BioArctic reports Leqembi approvals, partnerships, and JPY 143.5 billion sales forecast

BioArctic's Alzheimer's disease treatment, Leqembi, has seen significant progress during the second quarter of 2026, marked by new sales approvals and the establishment of strategic partnerships.

Eisai, the manufacturer of the drug, has issued a sales forecast for the company's fiscal year 2026 (April 2026 to March 2027), projecting total sales of Leqembi to reach JPY 143.5 billion. This forecast signals strong expectations for the drug's market performance.

The company did not specify which new approvals or partnerships are most critical. BioArctic continues its collaboration with Eisai on the development and commercialization of Leqembi. Future quarters will reveal how the drug establishes itself in the competitive Alzheimer's market.

While specific financial details for the reporting period were not disclosed, the sales forecast suggests a robust growth outlook for Leqembi.